Physician profile
Scott Andrew Silver
NPI 1326333071
$1,767.47
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $32.67 · 2021: $312 · 2022: $552 · 2023: $224 · 2024: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.27 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $738.15 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $353.86 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $128.29 | 2019-2024 | Camzyos |
| Veran Medical Technologies, INC. | $106.67 | 2019 | |
| Intuitive Surgical, INC. | $105.64 | 2022 | |
| Novo Nordisk INC | $99.63 | 2021-2022 | |
| Abbvie INC. | $36.53 | 2022 | |
| Amarin Pharma, INC. | $33.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $31.34 | 2019 | |
| Dexcom, INC. | $29.72 | 2019-2022 | |
| Baxter Healthcare | $18.10 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $16.05 | 2022 | |
| Abbott Laboratories | $15.75 | 2024 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $14.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.24 | 2023 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.28 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.